The National Radiotherapy Implementation Group have finally produced their recommendations to Commissioners and Clinicians regarding the commissioning, and use of SBRT (see link below). It is very worthwhile reading it, as it will be very useful for those who require funding for stereotactic radiotherapy such as Cyberknife or TomoTherapy.
Firstly, it makes clear that commissioning of SBRT should become the responsibility of the new Nationalised Commissioning Group (not GP commissioners).
Secondly, it recommends that SBRT is commissioned for the following cancers Lung Cancer ,Prostate Cancer ,Head & Neck cancer, Hepatic cancer ,Renal Cancer, Oligometastases, Spinal tumours,
Pancreatic cancer.
Thirdly, it suggests the above list should be a minimum, not maximum list.
Fourth, it suggests that commissioners should offset the cost of SBRT, by the savings it can produce (e.g, SBRT can delay the point when chemo is required).
I am personally very pleased with this report, because it supports all the points I have been making in my numerous letters to commissioners and policy makers (as well as on this forum). Also, while Commissioners are not compelled to accept the recommendations, it makes it increasingly difficult for them to resist funding. This is not the end of the funding war, but it certainly marks the beginning of the end.
ncat.nhs.uk/sites/default/files/NRIG%20SBRT.pdf